Experimental Clinical Trials
Here are the 6 most popular medical studies for experimental
Barrier Method
HydroGlyde Condom for Condom Users
Latex condoms have long been available as contraceptive devices as well as an effective means of preventing the spread of sexually transmitted infections. However, lack of adequate lubrication leads to inconsistent and incorrect condom use. The latex HydroGlyde condom has a hydrophilic coating which maintains its lubricity when in contact with water. Improved lubrication during intercourse may lead to improved user satisfaction and increased condom use which would help prevent the spread of Sexually Transmitted Infections and unwanted pregnancies. The primary objective of this study is to evaluate the preference, performance (breakage, slippage), safety (adverse events) and acceptability of a HydroGlyde prototype condom compared to a commercial latex condom with silicone lubricant. A secondary objective of this study is to compare and evaluate various lubricant activation methods for reliability, usability, and user preference.
Popular filter options for experimental trials
Experimental Clinical Trials With No Placebo
View 27 experimental medical studies that do not have a placebo group.
Behavioral Intervention
Employment for Reducing Violence and Crime
Chicago's Department of Family and Support Services will be providing summer employment and social-emotional skill training to youth over the summer of 2012. The investigators are partnering with them to evaluate the effects of the program. The investigators will track applicants to the program through existing administrative databases to assess the short- and long-term effects of the government's program. The investigators hypothesize that the program will decrease violence involvement and criminal activity, increase schooling engagement, and increase future employment outcomes.
Prosthetics
Experimental Prosthetic Foot (K3 Promoter) for Amputation
The investigators are currently verifying early data showing that the K3 Promoter prosthetic foot affects walking efficiency or stability in transtibial, unilateral amputees when compared to their current prostheses. Phase II funds are being used to address these metrics. These studies are important basic research, however, while Tensegrity has the unique opportunity to study amputee gait and movement in the CGMA's state-of-the-art facility the investigators will expand these studies with BRDG-SPAN funding by studying the following metrics: Four Square Step Test (FSST) Amputee Mobility Predictor (AMP) Timed Up and Go Test (TUG) Quality of life (QOL) index (SF-36) Activity-specific Balance Confidence Questionnaire (ABC) 3D motion analysis
View More Experimental Trials
See another 6 medical studies focused on experimental.
Frequently Asked Questions
Introduction to experimental
What are the top hospitals conducting experimental research?
In the realm of medical advancements, clinical trials for experimental treatments hold tremendous promise. Among the leading hospitals conducting such trials, Seattle Cancer Care Alliance in Seattle shines as a beacon of hope. Currently engaged in three active experimental trials, this institution is dedicated to exploring innovative approaches and pushing boundaries in cancer treatment. Beth Israel Deaconess Medical Center in Boston also embraces the spirit of discovery with two ongoing experimental trials that are contributing to cutting-edge research efforts. Meanwhile, Oregon Health & Science University in Portland stands at the forefront of medical innovation by actively participating in two experimental trials aimed at uncovering novel therapies. Joining these prestigious institutions is Massachusetts General Hospital, another renowned medical center where researchers are diligently working on two active experimental trials to push forward frontiers previously unexplored.
In New york City's Mount Sinai Hospital, scientists and physicians are blazing new trails through their involvement in two current experimental trials. By continually seeking out uncharted territories and delving into unconventional ideas within the field of medicine, these top hospitals embody a relentless pursuit of better treatment options for patients.
Although each hospital may have no recorded past experiments yet due to their focus on emerging methodologies or unique investigations; it is precisely this pioneering spirit that drives them towards future breakthroughs - placing them at the forefront of healthcare innovation and nurturing optimism for countless individuals seeking alternative paths towards improved health outcomes
Which are the best cities for experimental clinical trials?
When it comes to experimental clinical trials, several cities offer promising opportunities for participation. New york, New York stands out with 10 active trials exploring treatments like TRV027, fluorouracil, and Pembrolizumab. Seattle, Washington follows closely behind with 9 ongoing studies focusing on BMS-986165, Pembrolizumab, and fluorouracil interventions. Additionally, Chicago, Illinois showcases 8 active trials investigating potential breakthroughs such as Experiment 1 and Oral Micronized Progesterone 200mg. These cities are joined by Boston, Massachusetts which offers 7 active trials studying treatments including fluorouracil and Interferon Gamma-1b. Lastly, Atlanta, Georgia provides access to 6 active trials examining innovative options like TRV027 and Treatment approaches. With their commitment to research advancements in healthcare delivery, these cities present individuals with the opportunity to contribute to pioneering medical discoveries through experimental clinical trials.
Which are the top treatments for experimental being explored in clinical trials?
The top treatments currently being explored in clinical trials for breast cancer are daratumumab, belantamab mafodotin, and lenalidomide.
- Daratumumab: This powerful drug is being tested in six active trials specifically focused on breast cancer. It has been listed since 2012 and has a total of 134 all-time breast cancer trials.
- Belantamab mafodotin: This treatment shows promise with four ongoing clinical trials dedicated to studying its efficacy against breast cancer. Since its introduction in 2018, it has already been involved in a total of 26 all-time breast cancer trials.
- Lenalidomide: A well-established player in the field, lenalidomide is currently being investigated in three active clinical trials for breast cancer. With an impressive history dating back to 2003, it has participated in a remarkable total of 280 all-time clinical trials across various indications.
These treatments offer hope and potential breakthroughs for patients battling this challenging disease as researchers continue their tireless efforts to find effective solutions through rigorous clinical investigations.
What are the most recent clinical trials for experimental?
In the realm of experimental treatments, recent clinical trials have showcased promising developments that offer new possibilities for patients. Among them is ICI-Resistant, a phase 2 trial targeted at addressing immunotherapy resistance in cancer treatment. Additionally, the INFLUENZA G1 mHA Dose Level 2 study explores the potential benefits of combining Al(OH)3 with experimental influenza therapy. A large-scale phase 3 trial called "All participants" aims to evaluate an experimental intervention across a diverse population. Another intriguing avenue being explored is bacteriophage therapy in a combined phase 1 and phase 2 study. Lastly, cohort 1 of the PF-07081532 trial seeks to unveil potential therapeutic effects as part of its early-phase research efforts. These recent clinical trials provide optimism and hold promise for advancing our understanding and treatment options within the field of experimentation.
What experimental clinical trials were recently completed?
Several experimental clinical trials have recently concluded, showcasing the progress being made in medical research. Among these notable studies are the completion of a trial sponsored by Washington University School of Medicine in October 2021, investigating Uproleselan's potential for multiple myeloma treatment. Another significant milestone was reached in September 2021 with the conclusion of a trial conducted by the National Cancer Institute (NCI) on mRNA-1273. Additionally, AgenTus Therapeutics successfully wrapped up their agenT-797 study in January 2021. These completed trials represent important steps forward as scientists strive to uncover innovative approaches to combat various diseases and improve patient outcomes.